A Phase 4 interventional study of Metformin XR and Metformin IR in Type 2 Diabetes Mellitus, sponsored by Bristol-Myers Squibb. Completed at 156 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-29.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment of the 287 interventional ones that give a count, is one of 16 that started in 2013, is one of 98 in phase 4, and was the 178th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 16 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,736 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
19 studies in Diabetes Mellitus, Type 2 by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 19 finished, 3 (16%) have results posted.
Among the 19 studies in Diabetes Mellitus, Type 2 by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2013, is one of 3 in phase 4, and was the 18th registered.
Bristol-Myers Squibb’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
Among Bristol-Myers Squibb’s 19 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is determine if Metformin XR monotherapy in subjects with type 2 diabetes is non-inferior to Metformin IR monotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metformin Extended Release (XR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks Placebo matching with Metformin XR 0 mg tablets by mouth twice daily (BID) for 24 weeks
Drug: Metformin XR · Drug: Placebo matching with Metformin XR
Metformin Immediate Release (IR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks Placebo matching with Metformin IR 0 mg tablets by mouth twice daily (BID) for 24 weeks
Drug: Metformin IR · Drug: Placebo matching with Metformin IR
Also known as: Glucophage XR
Also known as: Glucophage
Adjusted Mean Change From Baseline in HbA1c
Mean change in glycated hemoglobin (HbA1c) from baseline to Week 24 in the double-blind treatment period.
Time frame: Baseline and Week 24
Number of Participants With Death, Serious Adverse Events (SAEs), SAEs Related to Study Therapy, SAEs Leading to Discontinuation, Adverse Events (AEs) Related to Study Therapy, and AEs Leading to Discontinuation
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Treatment-related=having certain, probable, possible, or missing relationship to study drug. All listed events are treatment emergent, which is defined as nonserious and serious AEs with an onset from Day 1 of the double-blind treatment up to and including 4 days and 30 days respectively, after the last dose date of double-blind study. randomized.
Time frame: Date of first dose (Day 1) up to 30 post last dose of study drug (approx. 28 weeks)
Mean Change in Fasting Plasma Glucose (FPG)
The mean change in fasting plasma glucose (FPG) from baseline to Week 24 in the double-blind treatment period was assessed. The lack of glycemic control criteria for initiation of rescue medication during Week 12 to Week 24 was having a FPG \> 200 mg/dL (11.1 mmol/L). mg/dL = milligrams per deciliter; mmol/L = millimole per Liter
Time frame: Baseline and Week 24
Mean Change in Mean Daily Glucose (MDG)
The mean change in Mean Daily Glucose (MDG) from baseline to Week 24 in the double-blind treatment period was assessed. Prior to the Day 1 visit (between Week -1 and Day 1) and in the week before the Week 24/Study Termination and Rescue or Early Treatment Termination visit, participants performed 7-point finger stick blood glucose monitoring (before and 2 hours after 3 meals per day, and at bedtime) for 3 consecutive days in order to determine their MDG.
Time frame: Baseline and Week 24
Percent of Participants With HbA1c < 7%
Percent of participants achieving a therapeutic glycemic response (defined as HbA1c \< 7.0%) at Week 24 in the double-blind treatment period.
Time frame: Week 24
1736 enrolled at 148 study sites in North America, Europe, and South Africa.Lead in period=794. Reasons not entered: 1 AE, 17 WC, 4 lost to FU, 3 NC, 911 SC, 4 ARS, 1 other. Adverse event=-AE, Withdrew consent=WC, Follow-up=FU, poor/non-compliance=NC, No longer met study criteria=SC, Administrative reason by sponsor=ARS.
| Milestone | Metformin XR | Metformin IR |
|---|---|---|
| Started | 283 | 285 |
| Completed | 268 | 271 |
| Not completed | 15 | 14 |
| Withdrew: Removed due to site non-compliance | 15 | 14 |
| Milestone | Metformin XR | Metformin IR |
|---|---|---|
| Started | 268 | 271 |
| Completed | 245 | 245 |
| Not completed | 23 | 26 |
| Withdrew: Adverse event | 6 | 1 |
| Withdrew: Subject request to discontinue treatment | 2 | 0 |
| Withdrew: Subject withdrew consent | 4 | 5 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 10 |
| Withdrew: Poor/non-compliance | 1 | 0 |
| Withdrew: Other | 6 | 10 |
| Milestone | Metformin XR | Metformin IR |
|---|---|---|
| Started | 9 | 1 |
| Completed | 6 | 1 |
| Not completed | 3 | 0 |
| Withdrew: Other | 2 | 0 |
| Withdrew: Subject withdrew consent | 1 | 0 |
Mean change in glycated hemoglobin (HbA1c) from baseline to Week 24 in the double-blind treatment period.
| percent | Metformin XR | Metformin IR |
|---|---|---|
| Adjusted Mean Change From Baseline in HbA1c | -0.93 ± 0.0485 | -0.96 ± 0.0480 |
The mean change in fasting plasma glucose (FPG) from baseline to Week 24 in the double-blind treatment period was assessed. The lack of glycemic control criteria for initiation of rescue medication during Week 12 to Week 24 was having a FPG \> 200 mg/dL (11.1 mmol/L). mg/dL = milligrams per deciliter; mmol/L = millimole per Liter
| mg/dL | Metformin XR | Metformin IR |
|---|---|---|
| Mean Change in Fasting Plasma Glucose (FPG) | -21.1 ± 1.803 | -20.6 ± 1.789 |
The mean change in Mean Daily Glucose (MDG) from baseline to Week 24 in the double-blind treatment period was assessed. Prior to the Day 1 visit (between Week -1 and Day 1) and in the week before the Week 24/Study Termination and Rescue or Early Treatment Termination visit, participants performed 7-point finger stick blood glucose monitoring (before and 2 hours after 3 meals per day, and at bedtime) for 3 consecutive days in order to determine their MDG.
| mg/dL | Metformin XR | Metformin IR |
|---|---|---|
| Mean Change in Mean Daily Glucose (MDG) | -24.68 ± 1.5813 | -27.05 ± 1.555 |
Percent of participants achieving a therapeutic glycemic response (defined as HbA1c \< 7.0%) at Week 24 in the double-blind treatment period.
| percent of participants | Metformin XR | Metformin IR |
|---|---|---|
| Percent of Participants With HbA1c < 7% | 70.9 (65.5 to 76.3) | 72.0 (66.3 to 77.7) |
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Treatment-related=having certain, probable, possible, or missing relationship to study drug. All listed events are treatment emergent, which is defined as nonserious and serious AEs with an onset from Day 1 of the double-blind treatment up to and including 4 days and 30 days respectively, after the last dose date of double-blind study. randomized.
| participants | Metformin XR | Metformin IR |
|---|---|---|
| Death | 1 | 0 |
| SAE | 8 | 10 |
| SAEs Related to Study Therapy | 1 | 1 |
| SAEs Leading to Discontinuation | 0 | 1 |
| AEs Related to Study Therapy | 30 | 25 |
| AEs Leading to Discontinuation | 10 | 7 |
Collected over From Day 1 up to 30 days post last dose (approx. 28 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metformin XR | — | 8/283 (2.8%) | 25/283 (8.8%) |
| Metformin IR | — | 10/285 (3.5%) | 22/285 (7.7%) |
| Event | Metformin XR | Metformin IR |
|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 2/283 | 0/285 |
| Hypocoagulable stateBlood and lymphatic system disorders | 1/283 | 0/285 |
| Angina unstableCardiac disorders | 1/283 | 0/285 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/283 | 0/285 |
| CholelithiasisHepatobiliary disorders | 1/283 | 0/285 |
| Delayed recovery from anaesthesiaInjury, poisoning and procedural complications | 1/283 | 0/285 |
| Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/283 | 0/285 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/283 | 0/285 |
| Cerebral haemorrhageNervous system disorders | 1/283 | 0/285 |
| DiplopiaEye disorders | 0/283 | 1/285 |
| Event | Metformin XR | Metformin IR |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 25/283 | 22/285 |
All Treated Data Set (n=568) are the randomized participants who received at least 1 dose of study drug during the double blind treatment period (up to rescue). 29 participants were excluded from the baseline Randomized Data Set; therefore, the number of participants included in the baseline population is 539. n = number of evaluable participants
| Age, Continuous(years) | Metformin XR | Metformin IR | Total |
|---|---|---|---|
| Mean | 56.8 ± 10.69 | 55.3 ± 10.34 | 56.0 ± 10.53 |
| Age, Customized(participants) | Metformin XR | Metformin IR | Total |
|---|---|---|---|
| < 65 years | 198 | 226 | 424 |
| >= 65 years | 70 | 45 | 115 |
| Sex: Female, Male(Participants) | Metformin XR | Metformin IR | Total |
|---|---|---|---|
| Female | 122 | 122 | 244 |
| Male | 146 | 149 | 295 |
| Race/Ethnicity, Customized(participants) | Metformin XR | Metformin IR | Total |
|---|---|---|---|
| White | 227 | 225 | 452 |
| Black or African American | 22 | 19 | 41 |
| Asian | 17 | 20 | 37 |
| Other | 2 | 7 | 9 |
Showing the first 100 of 156 sites across 10 countries. Choose a country and city above to see the rest.
Ran from Jun 2013 to primary completion in Jun 2016, 35 months.
Results were first posted in Jul 2017, 1 year 1 month after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 35 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin